US EditionPublished • loading... • Updated
Amneal announces BLA submission of biosimilar candidate to XOLAIR
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amneal announces BLA submission of biosimilar candidate to XOLAIR
BRIDGEWATER, N.J. —Amneal Pharmaceuticals has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for a proposed biosimilar to XOLAIR (omalizumab), developed by Kashiv BioSciences, LLC. XOLAIR is a registered trademark of Novartis AG.Omalizumab, a humanized monoclonal antibody that targets free IgE, is indicated for the treatment of moderate to severe persistent asthma (6 years and older pat…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
